ResMed Q4 Earnings Call Highlights
ResMed (NYSE:RMD) reported Q4 non-GAAP gross margin up 90 bps to 62.3% YoY, citing productivity and supply-chain efficiency, but down ~50 bps sequentially due to higher component and freight costs and a ~20-bp FX headwind. The company set a $42M Astral field safety provision and guided FY2027 reported revenue $5.75B-$5.85B and non-GAAP EPS $12.00-$12.25, plus $1.5B buybacks and a 10% dividend increase.
How this was made
The 30-second read
Why it matters
Traders can update models for fiscal 2027 revenue, EPS, and margin trajectory, while also reassessing risk around the Astral corrective action and the planned suspension of new Astral sales through fiscal 2027.
Market read
Fiscal 2027 guidance and the quantified Astral revenue and EPS headwinds are the core decision inputs for positioning after the call.
What to watch
The guidance assumes a ~50 bps FX headwind and includes dilution impacts from MatrixCare and Noctrix; deviations in FX, integration pace, or component/freight costs could swing outcomes versus the call narrative.
Background
The piece summarizes ResMed’s Q4 earnings call, focusing on non-GAAP margin, Astral field safety costs, and fiscal 2027 guidance plus portfolio changes.
Ticker impact
ResMed guided fiscal 2027 non-GAAP EPS to $12.00 to $12.25 and disclosed an Astral sales suspension creating a ~$75M revenue headwind.
Likely choppy reaction risk, with upside if margin and core growth offset the Astral headwind, and downside if investors focus on the revenue/EPS drag.
The article provides specific fiscal 2027 revenue, EPS, gross margin expansion direction, and quantified Astral headwind, which are direct inputs to valuation and positioning.
Market effects
Sleep-disordered breathing device peers may see read-across on margin durability, supply-chain productivity, and GLP-1-related PAP adoption signals.
Limited direct regional impact beyond the stated FX headwind assumption and AirCurve rollout geographies.
Astral field safety corrective action and sales suspension could influence global device compliance and patient prioritization narratives.
Counterpoint
Investors may over-penalize the Astral headwind; the company frames margin expansion and supply-chain productivity as offsetting factors, plus meaningful buybacks and dividend growth.
Key entities
- companyResMed
Guided fiscal 2027 revenue and non-GAAP EPS, disclosed Astral field safety provision, and outlined portfolio actions (Noctrix acquisition integration, MatrixCare divestiture).
- productAstral
Device subject to a field safety notice, with a $42M provision and a planned suspension of new sales during fiscal 2027.
- business unitMatrixCare
Planned divestiture around Sept. 1, with stated revenue and non-GAAP operating profit contribution and EPS dilution assumptions.
- business unitNoctrix
Acquired June 1, with integration underway and EPS dilution assumptions included in fiscal 2027 guidance.
